Home > Oncology > ASCO 2019 > Lung Cancer > Pembrolizumab Monotherapy Leads to 5-year Survival in Some Patients with NSCLC

Pembrolizumab Monotherapy Leads to 5-year Survival in Some Patients with NSCLC

Presented By
Dr Edward B. Garon, the David Geffen School of Medicine, USA
Conference
ASCO 2019
Trial
Phase 1, KEYNOTE-001

Medical writer: Jasenka Piljac Žegarac, PhD

Pembrolizumab monotherapy induces a durable anti-tumour response in patients with advanced non–small cell lung cancer (NSCLC), according to 5-year data from KEYNOTE-001—the first clinical trial evaluating pembrolizumab in advanced NSCLC (Abstract LBA9015).

“This is the longest follow-up for a large population of treatment-naive and previously treated patients with NSCLC treated with an inhibitor of the PD-1 immune checkpoint,” lead author Edward B. Garon, MD, MS, of the David Geffen School of Medicine, University of California/TRIO-US Network, said. “Not only were we able to induce durable responses, but now we have 5-year follow-up for this patient population.”

KEYNOTE-001 is a phase Ib, randomized, open-label study evaluating pembrolizumab in several different types of locally advanced or metastatic cancers. Cohorts C and F aimed to assess the safety, tolerability, and efficacy of pembrolizumab in patient...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on